References

  1. National Comprehensive Cancer Network. Non–Small Cell Lung Cancer (Version 6.2020). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 29, 2020.
  2. National Comprehensive Cancer Network. Colon Cancer (Version 4.2020). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed July 8, 2020.
  3. National Comprehensive Cancer Network. Breast Cancer (Version 4.2020). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July 8, 2020.
  4. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed July 8, 2020.
  5. Flaig TW, Spiess PE, Agarwal N, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(3):329-354:doi:10.6004/jnccn.2020.0011.
  6. National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 5.2020). https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed July 8, 2020.
  7. National Comprehensive Cancer Network. Uterine Neoplasms (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed July 8, 2020.
  8. National Comprehensive Cancer Network. Gastric Cancer (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed July 24, 2020.
  9. National Comprehensive Cancer Network. Soft Tissue Sarcoma (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed July 24, 2020.
  10. National Comprehensive Cancer Network. Cutaneous Melanoma (Version 3.2020). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma. PDF. Accessed July 8, 2020.
  11. National Comprehensive Cancer Network. Ovarian Cancer – Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed July 8, 2020.
  12. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed July 8, 2020.
  13. NCCN National Comprehensive Cancer Network. Thyroid Carcinoma (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed July 8, 2020.
  14. Laufer-Geva S, Rozenblum AB, Twito T, et al. The clinical impact of comprehensive genomic testing of circulating cell-free DNA in advanced lung cancer. J Thorac Oncol. 2018;13(11):1705-1716.
  15. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non–small cell lung cancer. J Clin Oncol. 2016;34:2980-2987.
  16. Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1–selected advanced non–small cell lung cancer (BIRCH). J Clin Oncol. 2017;35:2781-2789.
  17. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer (NSCLC): a retrospective analysis. Clin Cancer Res. 2016;22(18):4585-4593.
  18. Dudnik E, Peled N, Nechushtan H, et al. BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J Thorac Oncol. 2018;13(8):1128-1137.
  19. Paik PK, Felip E, Veillon R, et al. Tepotinib in non–small cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931-943.
  20. Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113-125.
  21. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829-838.
  22. Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.
  23. Garajová I, Giovannetti E, Biasco G, Peters GJ. c-Met as a target for personalized therapy. Transl Oncogenomics. 2015;7:Suppl 1:13-31.
  24. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer. Clin Cancer Res. 2019;25:4691-4700.
  25. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer. JAMA Oncol. 2019;5(2):173-180.
  26. Gutierrez ME, Choi K, Lanman RB, et al. Genomic profiling of advanced non–small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer. 2017;18(6):651-659.
  27. Kim ST, Banks KC, Lee S-H, et al. Prospective feasibility study for using cell-free circulating tumor DNA–guided therapy in refractory metastatic solid cancers: an interim analysis. Precis Oncol. 2017;1:1-15. doi:10.1200/PO.16.00059.